• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novartis

Here are the pharma companies accused of blocking generic competition

May 17, 2018 By Sarah Faulkner

Pills

To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, Celgene, FDA, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Novartis, Valeant Pharmaceuticals

Update: Novartis paid more than $1m to consulting company linked to Trump attorney Michael Cohen

May 9, 2018 By Sarah Faulkner

Novartis

Updated 5/9 to include new information about Novartis’ payments to Essential Consultants.  Novartis (NYSE:NVS) found itself in the middle of a national scandal today after it was revealed that the drugmaker paid more than $1 million to a consulting firm linked to President Donald Trump’s personal attorney, Michael Cohen. The shell company, Essential Consultants, was used by […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Novartis

Following first profitable quarter, Vericel’s CEO looks to grow portfolio of autologous cell therapy products

April 26, 2018 By Sarah Faulkner

vericel

In its latest financial results, Cambridge, Mass.-based Vericel (NSDQ:VCEL) saw sales climb 60% for its permanent skin-replacement product, Epicel, designed for patients with severe burns. Sales for its autologous cellular scaffold, Maci, were up 20% following its launch to the commercial market. Vericel’s growing product adoption helped to fuel the company’s first profitable quarter, according to […]

Filed Under: Clinical Trials, Featured, Implants, Regenerative Medicine, Regulatory/Compliance, Wall Street Beat Tagged With: Novartis, Vericel Corp

Pear Therapeutics, Sandoz ink deal for prescription digital therapeutics

April 19, 2018 By Sarah Faulkner

Pear Therapeutics

Pear Therapeutics revealed yesterday that it agreed to deal commercialization rights of its digital therapeutics to Novartis (NYSE:NVS) division Sandoz. The company’s reSET substance use disorder therapy became the first prescription digital therapeutic approved by the FDA in September last year. reSET-O, a digital therapeutic designed for people suffering from opioid use disorder, is under review […]

Filed Under: Business/Financial News, Featured, mHealth (Mobile Health), Patient Monitoring, Wall Street Beat Tagged With: Novartis, peartherapeutics, sandoz

Novartis, Harvard team up to develop immunotherapy drug-delivery systems

March 21, 2018 By Sarah Faulkner

Novartis

Novartis (NYSE:NVS), Harvard University and the Dana-Farber Cancer Institute are teaming up to develop the next generation of implantable and injectable biomaterials designed to delivery immunotherapies, the group reported today. Researchers from Harvard’s Wyss Institute for Biologically Inspired Engineering have worked for years to create systems that provide targeted, sustained delivery of immuno-oncology products. Now, Novartis […]

Filed Under: Drug-Device Combinations, Featured, Immunotherapy, Implants, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Harvard University, Novartis, Wyss Institute

Sandoz wins FDA nod for generic, injectable MS drug

February 13, 2018 By Sarah Faulkner

Sandoz

Sandoz said today that the FDA has approved its Glatopa glatiramer acetate injection as a generic version of Copaxone to treat relapsing forms of multiple sclerosis. The therapy, which is given three days per week, is administered using the Glatopaject injection device. The 20 mg/mL version of the MS treatment has been available in the […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Novartis, sandoz

Rani Therapeutics nabs $53m for robotic pill injection tech

February 8, 2018 By Sarah Faulkner

Rani Therapeutics

Rani Therapeutics has raised $53 million to support manufacturing as it gears up for clinical trials of its robotic pill technology. New investors like GeneScience Pharmaceuticals and Shire (NSDQ:SHPG) joined existing investors like Alphabet’s GV, Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN). Rani Therapeutics, an InCube Lab spin-out started in 2012, has developed a capsule that delivers an intestinal injection […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Allergan, AstraZeneca plc, Novartis, ranitherapeutics, Shire

FDA rejects Novartis’ Advair generic, leaving GSK without rival

February 8, 2018 By Sarah Faulkner

GlaxoSmithKline

GlaxoSmithKline (NYSE:GSK) was granted a temporary win today after Novartis‘ (NYSE:NVS) Sandoz unit reported that the FDA rejected its application for a generic version of the company’s blockbuster lung treatment, Advair. The regulatory agency reportedly told Novartis that it needs to submit additional clinical data before the FDA can make its final decision. GSK said in […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc, Novartis, sandoz

Study: Long-term use of inhaled corticosteroids may heighten risk of bone fractures in COPD patients

February 6, 2018 By Sarah Faulkner

asthma inhaler

Researchers reported this month that in men and women with chronic obstructive pulmonary disease, long-term use of inhaled corticosteroids may be linked to an increased risk of bone fractures. Previous research has shown that the inhaled drugs, used to treat COPD, impact bone mineral density based on the dose of the corticosteroid, especially in post-menopausal […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Orthopedics, Pharmaceuticals, Research & Development Tagged With: Novartis

NASA scientists take on muscular atrophy with drug-loaded implant

January 29, 2018 By Sarah Faulkner

Scientists aboard the International Space Station plan to study if a drug-eluting implant can prevent, slow or even turn back the muscular breakdown observed in astronauts when they fly for an extended period of time. The investigation is designed to test the efficacy of a drug and a nano-channel drug-delivery system in a space-bound mouse […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials, Research & Development Tagged With: Novartis

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 8
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS